Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Stuart L. Silverman(Cedars-Sinai Medical Center), Arkadi Chines(Procter & Gamble (United States)), José Zanchetta(Universidad del Salvador), Slobodan Vukičević(University of Zagreb), Harry K. Genant(University of California, San Francisco), Ginger D. Constantine(Université Constantine 2), Tobie J. de Villiers(North American Menopause Society), Claus Christiansen(VA Eastern Colorado Health Care System)
Cited by 505
Related Papers
The diagnosis of osteoporosis
|Journal of Bone and Mineral Research|1994|3.9k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k